Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States.
+ 1 more risk
Fair value with imperfect balance sheet.
Share Price & News
How has Assertio Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ASRT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ASRT underperformed the US Pharmaceuticals industry which returned -12.2% over the past year.
Return vs Market: ASRT underperformed the US Market which returned -11.5% over the past year.
Price Volatility Vs. Market
How volatile is Assertio Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StDoes Assertio Therapeutics (NASDAQ:ASRT) Have A Healthy Balance Sheet?
3 weeks ago | Simply Wall StNeed To Know: Assertio Therapeutics, Inc. (NASDAQ:ASRT) Insiders Have Been Buying Shares
1 month ago | Simply Wall StInvestors Who Bought Assertio Therapeutics (NASDAQ:ASRT) Shares Five Years Ago Are Now Down 92%
Is Assertio Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ASRT ($0.65) is trading below our estimate of fair value ($14.24)
Significantly Below Fair Value: ASRT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ASRT is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ASRT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ASRT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ASRT is good value based on its PB Ratio (0.9x) compared to the US Pharmaceuticals industry average (2.5x).
How is Assertio Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ASRT's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if ASRT's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ASRT's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ASRT's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ASRT's Return on Equity is forecast to be high in 3 years time
How has Assertio Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ASRT is currently unprofitable.
Growing Profit Margin: ASRT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of -30.1% per year.
Accelerating Growth: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: ASRT has a negative Return on Equity (-374.76%), as it is currently unprofitable.
How is Assertio Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ASRT's short term assets ($104.0M) do not cover its short term liabilities ($184.6M).
Long Term Liabilities: ASRT's short term assets ($104.0M) do not cover its long term liabilities ($284.7M).
Debt to Equity History and Analysis
Debt Level: ASRT's debt to equity ratio (606.1%) is considered high.
Reducing Debt: ASRT's debt to equity ratio has increased from 63.1% to 606.1% over the past 5 years.
Inventory Level: ASRT has a low level of unsold assets or inventory.
Debt Coverage by Assets: ASRT's debt is not covered by short term assets (assets are 0.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ASRT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ASRT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.4% per year.
What is Assertio Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ASRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ASRT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ASRT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ASRT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ASRT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Art Higgins (63yo)
Mr. Arthur Joseph Higgins, also known as Art, has been Chief Executive Officer, President and Director of Depomed, Inc. since March 28, 2017. Mr. Higgins founded Ascendancy Healthcare, Inc. in 2011 and ser ...
CEO Compensation Analysis
Compensation vs Market: Art's total compensation ($USD4.78M) is above average for companies of similar size in the US market ($USD601.33K).
Compensation vs Earnings: Art's compensation has been consistent with company performance over the past year.
|CEO, President & Director||3yrs||US$4.78m||0.52% $274.8k|
|CFO, Principal Accounting Officer & Senior VP||1.25yrs||US$955.40k||0.13% $67.1k|
|Senior VP and Chief Scientific & Technical Officer||1yr||US$2.33m||0.055% $29.2k|
|Senior Vice President of Human Resources & Administration||2.17yrs||no data||no data|
|Senior VP||no data||no data||no data|
|Senior VP & Chief Commercial Officer||2.33yrs||no data||no data|
|Director of Human Resources||no data||no data||no data|
Experienced Management: ASRT's management team is considered experienced (2.2 years average tenure).
|CEO, President & Director||3yrs||US$4.78m||0.52% $274.8k|
|Independent Director||16.33yrs||US$275.00k||0.22% $118.4k|
|Independent Director||3yrs||US$276.00k||0.035% $18.4k|
|Independent Chairman of the Board||3yrs||US$288.00k||0.083% $43.7k|
|Independent Director||3.42yrs||US$273.00k||0.050% $26.7k|
|Independent Director||1.08yrs||no data||0.018% $9.4k|
|Independent Director||11.92yrs||US$263.50k||0.075% $39.5k|
|Director||0.50yr||no data||no data|
|Independent Director||1yr||no data||no data|
Experienced Board: ASRT's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.9%.
Assertio Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Assertio Therapeutics, Inc.
- Ticker: ASRT
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$52.837m
- Shares outstanding: 81.29m
- Website: https://www.assertiotx.com
Number of Employees
- Assertio Therapeutics, Inc.
- 100 South Saunders Road
- Suite 300
- Lake Forest
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ASRT||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Dec 1997|
|DPOA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 1997|
Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018. Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 01:38|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.